Agenda

Date and TimeTitle
Jan 28, 2022
3:00pm - 3:40pm (Eastern)
ICLUSIG®(ponatinib): Taking Action At The Critical Moment

Sponsored by Takeda Oncology

Jan 29, 2022
8:00am - 8:40am (Eastern)
Use of a Targeted Agent For Previously Untreated or R/R CLL

This program presents clinical efficacy and safety data supporting the use of a selective Bruton tyrosine kinase inhibitor for the treatment of previously untreated and R/R CLL.

Sponsored by AstraZeneca

Jan 29, 2022
9:00am - 10:42am (Eastern)
Session I

9:00 am ET | Welcome and Introduction
Hagop Kantarjian, MD

9:05 am ET | Acute Myeloid Leukemia
Courtney D. DiNardo, MD, MSCE

9:28 am ET | Live Q&A
Courtney D. DiNardo, MD, MSCE
Hagop Kantarjian, MD

9:36 am ET | Myelodysplastic Syndromes
Guillermo Garcia-Manero, MD

10:02 am ET | Live Q&A
Guillermo Garcia-Manero, MD
Hagop Kantarjian, MD

10:11 am ET | Chronic Myeloid Leukemia 
Jorge E. Cortes, MD

10:32 am ET | Live Q&A
Jorge E. Cortes, MD
Hagop Kantarjian, MD

10:41 am ET | Summary
Hagop Kantarjian, MD

Jan 29, 2022
10:43am - 11:05am (Eastern)
Break

JOIN US IN THE EXHIBIT HALL!

Jan 29, 2022
11:05am - 12:40pm (Eastern)
Session I, Continued

11:05 AM ET | Welcome Back
Hagop Kantarjian, MD

11:10 AM ET | Acute Lymphocytic Leukemia
Elias J. Jabbour, MD

11:33 AM ET | Live Q&A
Elias J. Jabbour, MD; Hagop Kantarjian, MD

11:42 AM ET | Chronic Lymphocytic Leukemia
Susan M. O'Brien, MD

12:02 PM ET | Live Q&A
Susan M. O'Brien, MD; Hagop Kantarjian, MD

12:11 PM ET | Myeloproliferative Neoplasms
Srdan Verstovsek, MD, PhD

12:32 PM ET | Live Q&A
Srdan Verstovsek, MD, PhD; Hagop Kantarjian, MD

12:41 PM ET | Summary
Hagop Kantarjian, MD

Jan 29, 2022
1:00pm - 1:40pm (Eastern)
Redefining Frontline Therapy In Patients With Multiple Myeloma*

This presentation will discuss redefining frontline therapy in patients with multiple myeloma (MM) using DARZALEX® and DARZALEX FASPRO®

*This presentation will be available on demand from February 1-April 1, 2022

Sponsored by Janssen

Feb 4, 2022
12:00pm - 12:35pm (Eastern)
Brukinsa for the treatment of adult patients with Waldenström’s macroglobulinemia (WM)

Sponsored by BeiGene

Feb 4, 2022
3:00pm - 3:20pm (Eastern)
Continuous Proteasome Inhibition with NINLARO® (ixazomib) Offers Durable Efficacy and Manageable Tolerability for the Types of Patients You See Every Day

Sponsored by Takeda Oncology

Feb 5, 2022
9:00am - 10:35am (Eastern)
Session II

9:00 am ET | Welcome and Introduction
Hagop Kantarjian, MD

9:06 am ET | Newly Diagnosed Multiple Myeloma
Sagar Lonial, MD

9:26 am ET | Live Q&A
Sagar Lonial, MD
Hagop Kantarjian, MD

9:37 am ET | Relapsed/Refractory Myeloma
S. Vincent Rajkumar, MD

9:52 am ET | Live Q&A
S. Vincent Rajkumar, MD
Hagop Kantarjian, MD

10:03 am ET | Hodgkin and Indolent Non-Hodgkin Lymphoma
Loretta J. Nastoupil, MD

10:24 am ET | Live Q&A
Loretta J. Nastoupil, MD
Hagop Kantarjian, MD

Feb 5, 2022
10:35am - 10:55am (Eastern)
Break

JOIN US IN THE EXHIBIT  HALL!

Feb 5, 2022
10:55am - 12:00pm (Eastern)
Session II, Continued

10:55 am ET I Welcome Back 
Hagop Kantarjian, MD

11:00 am ET | Aggressive Non-Hodgkin Lymphoma
Julie M. Vose, MD, MBA

11:21 am ET | Live Q&A
Julie M. Vose, MD, MBA
Hagop Kantarjian, MD

11:30 am ET | Benign Hematology
Stephan Moll, MD

11:53 am ET | Live Q&A
Stephan Moll, MD
Hagop Kantarjian, MD

12:01 pm ET | Summary
Hagop Kantarjian, MD

Feb. 22, 2022 - 3:30 pm to May. 23, 2022 - 3:30 pm (Eastern)Hematologic Malignancies Demystified - Jan 29 & Feb 5th